Biomarkers of liver injury for hepatitis clinical trials: A meta-analysis of longitudinal studies

Antiviral Therapy

Volumn 15, Issue 4, 2010, Pages 617-631

  Poynard, Thierry ^a,b   Ngo, Yen ^b   Munteanu, Mona ^b   Thabut, Dominique ^a   Massard, Julien ^a   Moussalli, Joseph ^a   Varaud, Anne ^a   Benhamou, Yves ^a   Ratziu, Vlad ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Biopredictive   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; BIOLOGICAL MARKER; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; ANTIVIRUS AGENT;

ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DISEASE COURSE; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; FIBROSIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER INJURY; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT RESPONSE; BIOPSY; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; LIVER; LIVER CIRRHOSIS; LONGITUDINAL STUDY; META ANALYSIS; PATHOLOGY; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; TREATMENT OUTCOME;

EID: 77955327158     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1570     Document Type: Article

References (51)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1:74-81.
2. Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet 2003; 362:2095-2100.
3. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34 Suppl 1:S1-S3. (Pubitemid 43197742)
4. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362:2089-2094.
5. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371:838-851.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
8. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020.
9. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
10. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
11. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134:1670-1681.
12. Poynard T, Morra R, Ingiliz P, et al. Biomarkers of liver fibrosis. Adv Clin Chem 2008; 46:131-152.
13. Castera L, Denis J, Babany G, Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J Hepatol 2007; 46:528-529. (Pubitemid 46201725)
14. McHutchison J, Poynard T, Afdhal N, International Fibrosis Group Meeting Participants. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin Gastroenterol Hepatol 2006; 4:1214-1220.
15. La Haute Autorité de Santé (HAS; France). The HAS recommendations for the management of the chronic hepatitis C using non-invasive biomarkers. (Updated December 2008. Accessed June 2010.) Available from http://www.has-sante.fr/portail/plugins/ModuleXitiKLEE/ types/FileDocument/ doXiti.jsp?id=c-783807
16. Fontaine H, Petitprez K, Roudot-Thoraval F, et al. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol 2007; 31:504-509.
17. European Medicines Agency. Guideline on the clinical evaluation of direct acting antiviral agents intended for treatment of chronic hepatitis C. (Updated May 2008. Accessed June 2010.) Available from www.ema.europa.eu/ pdfs/human/ewp/617203en.pdf
18. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7:40.
19. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 32:22-38.
20. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46:912-921.
21. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102:2589-2600.
22. Poynard T, Muntenau M, Morra R, et al. Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update. Gastroenterol Clin Biol 2008; 32:8-21.
23. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134:960-974.
24. Poynard T, Massard J, Rudler M, et al. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials. Gastroenterol Clin Biol 2009; 33:916-922.
25. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
26. Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008; 48:1070-1078.
27. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257-265.
28. Hintze JL. NCSS 2007 User Guide. Kaysville: Number Cruncher Statistical Systems software NCSS 2007; pp. 200.
29. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52:1887-1896.
30. Vergniol J, Foucher J, Castéra L, et al. Changes of noninvasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009; 16:132-140.
31. Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83:127-134.
32. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002; 9:128-133.
33. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38:481-492. (Pubitemid 36919870)
34. d'Arondel C, Munteanu M, Moussalli J, et al. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. J Viral Hepat 2006; 13:182-189.
35. Patel K, Benhamou Y, Yoshida EM, et al. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat 2009; 16:178-186.
36. Halfon P, Carrat F, Bédossa P, et al. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02. Antivir Ther 2009; 14:211-219.
37. Ngo Y, Benhamou Y, Thibault V, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE 2008; 3:e2573.
38. Poynard T, Ngo Y, Marcellin P, et al. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat 2009; 16:203-213.
39. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest- ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100:1970-1980.
40. Oliveri F, Coco B, Ciccorossi P, et al. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol 2008; 14:6154-6162.
41. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-832.
42. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418-431.
43. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of the hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-521.
44. Vispo E, Barreiro P, Del Valle J, et al. Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther 2009; 14:187-193.
45. Morra R, Lebray P, Ingiliz P, et al. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. Hepatology 2008; 47:353-354. (Pubitemid 351171076)
46. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007; 44:463-469.
47. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36:S161-S172.
48. Fontana RJ, Bonkovsky HL, Naishadham D, et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2009; 7:219-226.
49. Poynard T, Schiff ER, Terg R, et al. FibroTest (Ft) baseline value is an independent predictor of early (EVR) and sustained virological response (SVR) in non-responders patients re-treated with pegylated interferon alfa-2B (PEG-2B) and ribavirin in EPIC3. J Hepatol 2009; 50 Suppl 1:S156.
50. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359:2429-2441.
51. Poynard T, Ratziu V. Prolonged therapy for hepatitis C with low-dose peginterferon. N Engl J Med 2009; 360:1152. Author reply 1152-1153.